Startups
With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.
Overview
Location
United States, Washington, Seattle
Employees
11-50
Total raised
$20M
Founded date
2019
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 18, 2022 | Life Sciences Partners | lspvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 11, 2021 | Visus Therapeutics Raises $20M in Funding | Visus Therapeutics, Inc., a Seattle, WA- and and Orange County, Calif.,-based based clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, raised $20m in fu... |
| Aug 10, 2021 | Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners | Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline Strengthens its Board of Direct... |
| Mar 10, 2021 | Visus Therapeutics raises $36M from J&J’s VC arm, others to develop eye drop that treats presbyopia | Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $36 million. Johnson & Johnson Innovation, the venture capital arm of J&J, invested in the Series A round, in addition to RTW Investment... |
| Mar 9, 2021 | Visus Therapeutics Raises $36M in Series A Financing | Visus Therapeutics Inc., a Seattle, WA- Orange County, Calif.-based based clinical-stage pharmaceutical company developing a presbyopia-correcting eye drop, closed a $36m Series A financing. Backers included Johnson & Johnson Innovation... |
Reviews 0
FAQ about Visus Therapeutics, Inc.
When was Visus Therapeutics, Inc. founded?
Visus Therapeutics, Inc. was founded in 2019.
How much funding has Visus Therapeutics, Inc. raised?
Visus Therapeutics, Inc. has raised $20M in total across 1 funding round.
Who has invested in Visus Therapeutics, Inc.?
Parsers VC lists 2 investors of Visus Therapeutics, Inc., among them Life Sciences Partners.
What has the press written about Visus Therapeutics, Inc.?
Parsers VC has collected 5 articles mentioning Visus Therapeutics, Inc., among them “Visus Therapeutics Raises $20M in Funding” (Aug 11, 2021) and “Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners” (Aug 10, 2021).
Is Visus Therapeutics, Inc. still active?
Yes, Visus Therapeutics, Inc. is active; its latest activity on Parsers VC dates from Apr 18, 2022.